We could not find any results for:
Make sure your spelling is correct or try broadening your search.
VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed ... VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy. Show more
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update PR Newswire HENDERSON, Nev., Nov. 8, 2024 Conference call to take place on Friday, November 15 at 8:30...
Volition Appoints Timothy I. Still as Chairman PR Newswire HENDERSON, Nev., Nov. 6, 2024 HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a...
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating PR Newswire HENDERSON, Nev., Oct. 31, 2024 HENDERSON, Nev., Oct. 31, 2024 /PRNewswire/ -- VolitionRx...
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar PR Newswire HENDERSON, Nev., Oct. 9, 2024 HENDERSON, Nev., Oct. 9, 2024 /PRNewswire/ -- VolitionRx Limited...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1417 | 24.0169491525 | 0.59 | 0.76 | 0.58 | 177929 | 0.66650491 | CS |
4 | 0.0027 | 0.37037037037 | 0.729 | 0.76 | 0.55 | 105193 | 0.6504711 | CS |
12 | 0.1217 | 19.9508196721 | 0.61 | 0.9 | 0.55 | 120329 | 0.67727026 | CS |
26 | -0.1083 | -12.8928571429 | 0.84 | 0.9 | 0.4301 | 121778 | 0.66521123 | CS |
52 | -0.1194 | -14.0289037716 | 0.8511 | 1.23 | 0.4301 | 164576 | 0.78627527 | CS |
156 | -2.9183 | -79.9534246575 | 3.65 | 4.1401 | 0.4301 | 138311 | 1.47575894 | CS |
260 | -4.7683 | -86.6963636364 | 5.5 | 7.69 | 0.4301 | 184684 | 2.74481893 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions